Developer docs
API playgroundTry for free, no card

Search company profiles

Hemarina

Full company profile

uuid0009wfn

Namestring
Hemarina
Legal namestring
Hemarina SA
Websiteurl
hemarina.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Hemarina is a privately-held French biotechnology company founded in 2007 as a spin-off from CNRS and Sorbonne University, headquartered in Morlaix, Brittany. The company develops a portfolio of therapeutic and industrial products based on a single proprietary technology platform, M101, which leverages the extracellular hemoglobin extracted from the marine lugworm Arenicola marina. Hemarina controls its raw material supply end-to-end through the 13-hectare Ferme Marine de Noirmoutier aquaculture facility in France, producing approximately 30 tonnes of marine worms annually, and outsources industrial-scale manufacturing to Delpharm at their Tours, France plant.

The company's lead commercial product, HEMO2life®, is a CE-marked medical device additive to organ preservation solutions. It is described as universal across blood types, stable at ambient temperature for over two years, and capable of binding 40 times more oxygen than human hemoglobin, supporting applications in kidney, face, and limb transplantation. The broader product portfolio includes HEMOXYCarrier® (universal oxygen therapeutic), HEMHealing® (oxygenating wound dressing), HEMDental-Care® (periodontal treatment), HEMOXCell® and HEMBoost® (industrial bioproduction inputs), and HEMDental-Regenerativ® (dental bone regeneration).

Hemarina operates an enterprise field sales motion targeting hospital transplant centers, academic medical centers, and military medical institutions in France, Europe, the United States (via a Boston office and US Navy collaboration), and India (via the Amrita Institute of Medical Sciences partnership). The OxyOp2 multicentric trial with 460 patients across all French transplant centers is the company's pivotal clinical program. Notable milestones include the 2019 CE marking, the 2021 world's first bilateral upper limb transplant at AIMS in India, the 2022 face transplant of a French soldier with presidential validation, the 2023 Prix Galien France award in the medical device category, and the 2026 European Inventor Award finalist recognition for founder Dr. Franck Zal. Revenue figures are not publicly disclosed, and no US FDA approval has been announced.

Short descriptiontext

Hemarina is a French biotech developing therapeutic oxygen carriers derived from marine lugworm (Arenicola marina) hemoglobin. Its lead product HEMO2life® is a CE-marked medical device for organ preservation, serving hospitals, transplant centers, and military medical institutions across Europe, the US, and India.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMorlaix, France
HQ citystring
Morlaix
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oxygen carrier therapeutics, organ preservation devices, marine hemoglobin biotechnology, medical device manufacturing, wound healing hydrogels
Industry2 codes
PRIMARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SECONDARYHLAAAAAL
Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Biotechnology - Oxygen Carrier Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1HEMO2life® Medical Device Sales
TypeOne Time License
Description

Revenue generated from the sale of HEMO2life®, a medical device used for organ preservation and as an oxygen therapeutic. Sales are made directly to hospitals and medical institutions, primarily for transplant procedures, emergency medicine, and military medical applications. Revenue is recognized upon delivery to healthcare institutions following regulatory approvals and hospital procurement processes.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
Pricing details1 tier
1B2B institutional pricing for healthcare providers
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is quote-based and negotiated directly with hospital procurement departments. No public pricing tiers or list prices are available. Pricing varies by market (EU, India, US military), application type (organ preservation, emergency use), and order volume.

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1HEMO2life®
Description

Additive to organ preservation solutions - universal oxygen carrier medical device derived from Arenicola marina lugworm hemoglobin for graft preservation

hemarina.com
+6 more records
Core offering1 text field

Hemarina develops, manufactures, and sells medical devices and therapeutic products based on its proprietary M101 platform, leveraging extracellular hemoglobin extracted from the marine lugworm Arenicola marina. Its flagship HEMO2life® is a CE-marked organ preservation additive used in kidney, face, and limb transplants, while the broader portfolio addresses oxygen therapy, wound healing, dental care, and industrial bioproduction. The company sells these prescription products and bioprocessing inputs directly to hospitals, transplant centers, military medical institutions, and industrial customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 40 times greater oxygen-carrying capacity compared to human hemoglobin
+3 more records
Product overview1 text field

Hemarina is a biotechnology company with a proprietary technology platform (M101) based on extracellular hemoglobin extracted from the marine lugworm Arenicola marina. The company's product portfolio includes six therapeutic and industrial products: HEMO2life® (organ preservation additive), HEMOXYCarrier® (universal oxygen carrier), HEMHealing® (wound healing hydrogel), HEMDental-Care® (periodontal treatment gel), HEMOXCell® (cell growth activator), and HEMBoost® (bioproduction input). The M101 molecule is unique in that it is extracellular (not contained in red blood cells), universal (compatible with all blood types), binds 40 times more oxygen than human hemoglobin, and is 250 times smaller than human red blood cells. The products address ischemic diseases where oxygen delivery is compromised, including organ transplantation, wound healing, and dental applications.

Product and service6 records
1HEMO2life®
CategoryOrgan Preservation Medical Device
Description

CE-marked medical device additive to organ preservation solutions, derived from extracellular hemoglobin of the marine lugworm Arenicola marina. Binds 40 times more oxygen than human hemoglobin and reduces ischemia-reperfusion injury during graft preservation. Used by hospital transplant centers in kidney, face, and limb transplant procedures.

2HEMOXYCarrier®
CategoryTherapeutic Oxygen Carrier
Description

Universal therapeutic oxygen carrier based on the M101 hemoglobin platform for medical applications requiring direct oxygen delivery to tissues and organs. Designed for emergency transfusion, acute anemia treatment, and oxygenation support in hospital and military medicine settings.

3HEMHealing®
CategoryWound Care Hydrogel
Description

Oxygenating hydrogel wound dressing that releases physiological oxygen to damaged tissues to enhance regeneration and reduce healing time, with primary applications in burns and chronic wounds. Awarded the Prix Galien de l'Année 2023 in the medical device category.

4HEMDental-Care®
CategoryDental Therapeutic Hydrogel
Description

Oxygenating hydrogel for dental applications, designed for periodontal treatment with demonstrated anti-inflammatory and anti-bacterial properties for the management of periodontitis.

5HEMOXCell®
CategoryIndustrial Bioproduction Input
Description

Cell growth activator for industrial bioproduction applications. Leverages the oxygen-carrying properties of the M101 molecule to enhance cell viability and productivity in bioreactor systems for pharmaceutical and biotech manufacturing customers.

6HEMBoost®
CategoryIndustrial Bioproduction Input
Description

Input for industrial bioproduction designed to enhance productivity in biomanufacturing processes through improved oxygenation of cell cultures.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2018-11-29
Description

Manufacturing partnership with Delpharm, a leading pharmaceutical contract manufacturer, for the industrial-scale production of HEMO2life® medical device. This partnership enables Hemarina to scale manufacturing capacity beyond its pilot facilities while leveraging Delpharm's expertise in aseptic manufacturing and regulatory compliance for pharmaceutical products.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Clinical partnership with Amrita Institute of Medical Sciences in Kochi, India for the use of HEMO2life® in transplant procedures. AIMS performed the world's first bilateral upper limb transplant using HEMO2life® in 2016, establishing a landmark clinical reference case.

3Brest University Hospital (CHRU de Brest)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial partnership for the OxyOp2 study evaluating HEMO2life® in organ preservation applications. The hospital serves as a key clinical research site generating pivotal evidence for regulatory approvals and clinical adoption.

4Naval Medical Research Center / US Navy
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Preclinical collaboration with the US Navy's Naval Medical Research Center for military medical applications of HEMO2life®, including battlefield hemorrhage control, emergency field transfusion, and combat casualty care.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Develops dodecafluoropentane-based oxygen therapeutics for cancer, stroke, and other ischemic conditions. Competes in the same oxygen-carrier therapeutic space with alternative chemistry approach but overlapping indications.

TypeDirect peer
Description

Develops Thrombosomes (lyophilized platelets) and other blood-product substitutes for hemorrhage and trauma. Operates in the same blood-substitute therapeutic space with comparable emergency medicine and military positioning.

TypeBroad incumbent
Description

Swedish-listed organ preservation company with leading lung perfusion technology (Steen solution) and expanding into abdominal organ preservation. Established commercial player in the same transplant workflow where HEMO2life® is positioned as an additive.

TypeDirect peer
Description

Supplier of organ preservation solutions including Belzer UW and static cold storage products used as the baseline medium in transplant workflows. Competes directly with HEMO2life® as a preservation additive and could be a commercial channel partner.

TypeBroad incumbent
Description

Global plasma-derived therapies leader producing hemoglobin-based and plasma-based blood products. Represents the established incumbent in hematology and blood-related biologics that Hemarina's marine hemoglobin platform could eventually compete with or complement.

TypeBroad incumbent
Description

Develops normothermic machine perfusion technology for liver and kidney preservation. Represents the leading alternative platform to HEMO2life® in the organ preservation workflow, particularly in European transplant centers.

TypeDirect peer
Description

Developed Sanguinate, a PEGylated bovine hemoglobin-based oxygen carrier for sickle cell disease and other ischemic conditions. Directly comparable hemoglobin-based therapeutic platform pursuing similar hematology and oxygen-delivery indications.

8HbO2 Therapeutics
TypeDirect peer
Description

Develops Hemopure (hemoglobin-based oxygen carrier from bovine source) for surgery and trauma indications. Closest direct competitor in the HBOC therapeutic class with overlapping universal-donor positioning and surgical use cases.

9TransMedics Group
TypeBroad incumbent
Description

Market leader in normothermic organ preservation systems for lung, heart, and liver transplants. Competes indirectly with HEMO2life® by offering an alternative preservation paradigm that may absorb or substitute for hemoglobin-based additives.

TypeEmerging player
Description

Develops oxygen-loaded nanobubble therapeutics for stroke and oncology. Competes in the oxygen-delivery therapeutic space with a different delivery mechanism (nanobubbles vs. extracellular hemoglobin) but overlapping clinical applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hemarina

Medical Biotechnology - Oxygen Carrier Therapeuticshemarina.com

Hemarina is a French biotech developing therapeutic oxygen carriers derived from marine lugworm (Arenicola marina) hemoglobin. Its lead product HEMO2life® is a CE-marked medical device for organ preservation, serving hospitals, transplant centers, and military medical institutions across Europe, the US, and India.

What Hemarina does

Hemarina is a privately-held French biotechnology company founded in 2007 as a spin-off from CNRS and Sorbonne University, headquartered in Morlaix, Brittany. The company develops a portfolio of therapeutic and industrial products based on a single proprietary technology platform, M101, which leverages the extracellular hemoglobin extracted from the marine lugworm Arenicola marina. Hemarina controls its raw material supply end-to-end through the 13-hectare Ferme Marine de Noirmoutier aquaculture facility in France, producing approximately 30 tonnes of marine worms annually, and outsources industrial-scale manufacturing to Delpharm at their Tours, France plant.

The company's lead commercial product, HEMO2life®, is a CE-marked medical device additive to organ preservation solutions. It is described as universal across blood types, stable at ambient temperature for over two years, and capable of binding 40 times more oxygen than human hemoglobin, supporting applications in kidney, face, and limb transplantation. The broader product portfolio includes HEMOXYCarrier® (universal oxygen therapeutic), HEMHealing® (oxygenating wound dressing), HEMDental-Care® (periodontal treatment), HEMOXCell® and HEMBoost® (industrial bioproduction inputs), and HEMDental-Regenerativ® (dental bone regeneration).

Hemarina operates an enterprise field sales motion targeting hospital transplant centers, academic medical centers, and military medical institutions in France, Europe, the United States (via a Boston office and US Navy collaboration), and India (via the Amrita Institute of Medical Sciences partnership). The OxyOp2 multicentric trial with 460 patients across all French transplant centers is the company's pivotal clinical program. Notable milestones include the 2019 CE marking, the 2021 world's first bilateral upper limb transplant at AIMS in India, the 2022 face transplant of a French soldier with presidential validation, the 2023 Prix Galien France award in the medical device category, and the 2026 European Inventor Award finalist recognition for founder Dr. Franck Zal. Revenue figures are not publicly disclosed, and no US FDA approval has been announced.

Hemarina firmographics

Firmographics
Name
Hemarina
Legal name
Hemarina SA
Website
https://hemarina.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Hemarina is a French biotech developing therapeutic oxygen carriers derived from marine lugworm (Arenicola marina) hemoglobin. Its lead product HEMO2life® is a CE-marked medical device for organ preservation, serving hospitals, transplant centers, and military medical institutions across Europe, the US, and India.
Ownership category
akta.pro rank

Hemarina industry classification

Industry
Product category
Medical Biotechnology - Oxygen Carrier Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)
SIC
Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SECONDARYHLAAAAAL
Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Oxygen carrier therapeutics
  • Organ preservation devices
  • Marine hemoglobin biotechnology
  • Medical device manufacturing
  • Wound healing hydrogels

Where Hemarina is headquartered

Location

Headquarters

HQ city
Morlaix
HQ country
France
HQ region
Europe

Offices3 records

Markets served

Hemarina business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

  1. HEMO2life® Medical Device Sales: Revenue generated from the sale of HEMO2life®, a medical device used for organ preservation and as an oxygen therapeutic. Sales are made directly to hospitals and medical institutions, primarily for transplant procedures, emergency medicine, and military medical applications. Revenue is recognized upon delivery to healthcare institutions following regulatory approvals and hospital procurement processes.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B institutional pricing for healthcare providers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Hemarina product offering

Product offering

Core offering

Hemarina develops, manufactures, and sells medical devices and therapeutic products based on its proprietary M101 platform, leveraging extracellular hemoglobin extracted from the marine lugworm Arenicola marina. Its flagship HEMO2life® is a CE-marked organ preservation additive used in kidney, face, and limb transplants, while the broader portfolio addresses oxygen therapy, wound healing, dental care, and industrial bioproduction. The company sells these prescription products and bioprocessing inputs directly to hospitals, transplant centers, military medical institutions, and industrial customers.

Product overview

Hemarina is a biotechnology company with a proprietary technology platform (M101) based on extracellular hemoglobin extracted from the marine lugworm Arenicola marina. The company's product portfolio includes six therapeutic and industrial products: HEMO2life® (organ preservation additive), HEMOXYCarrier® (universal oxygen carrier), HEMHealing® (wound healing hydrogel), HEMDental-Care® (periodontal treatment gel), HEMOXCell® (cell growth activator), and HEMBoost® (bioproduction input). The M101 molecule is unique in that it is extracellular (not contained in red blood cells), universal (compatible with all blood types), binds 40 times more oxygen than human hemoglobin, and is 250 times smaller than human red blood cells. The products address ischemic diseases where oxygen delivery is compromised, including organ transplantation, wound healing, and dental applications.

Differentiator

Problem solved

Functional benefit

Brands

  • HEMO2life®: Additive to organ preservation solutions - universal oxygen carrier medical device derived from Arenicola marina lugworm hemoglobin for graft preservation
  • HEMOXYCarrier®
  • HEMHealing®
  • HEMDental-Care®
  • HEMDental-Regenerativ®
  • HEMOXCell®
  • HEMBoost®

Products and services

  • HEMO2life® CE-marked medical device additive to organ preservation solutions, derived from extracellular hemoglobin of the marine lugworm Arenicola marina. Binds 40 times more oxygen than human hemoglobin and reduces ischemia-reperfusion injury during graft preservation. Used by hospital transplant centers in kidney, face, and limb transplant procedures.
  • HEMOXYCarrier® Universal therapeutic oxygen carrier based on the M101 hemoglobin platform for medical applications requiring direct oxygen delivery to tissues and organs. Designed for emergency transfusion, acute anemia treatment, and oxygenation support in hospital and military medicine settings.
  • HEMHealing® Oxygenating hydrogel wound dressing that releases physiological oxygen to damaged tissues to enhance regeneration and reduce healing time, with primary applications in burns and chronic wounds. Awarded the Prix Galien de l'Année 2023 in the medical device category.
  • HEMDental-Care® Oxygenating hydrogel for dental applications, designed for periodontal treatment with demonstrated anti-inflammatory and anti-bacterial properties for the management of periodontitis.
  • HEMOXCell® Cell growth activator for industrial bioproduction applications. Leverages the oxygen-carrying properties of the M101 molecule to enhance cell viability and productivity in bioreactor systems for pharmaceutical and biotech manufacturing customers.
  • HEMBoost® Input for industrial bioproduction designed to enhance productivity in biomanufacturing processes through improved oxygenation of cell cultures.

Quantifiable outcome

  • 40 times greater oxygen-carrying capacity compared to human hemoglobin
  • +3 more outcomes

Companies that use Hemarina

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Hemarina technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Hemarina partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, flagship and major.

  • DelpharmcoreOEM/ Whitelabel/ Licensing Partner · 29 November 2018Manufacturing partnership with Delpharm, a leading pharmaceutical contract manufacturer, for the industrial-scale production of HEMO2life® medical device. This partnership enables Hemarina to scale manufacturing capacity beyond its pilot facilities while leveraging Delpharm's expertise in aseptic manufacturing and regulatory compliance for pharmaceutical products.
  • Amrita Institute of Medical Sciences (AIMS)flagshipStrategic or Co-development PartnerClinical partnership with Amrita Institute of Medical Sciences in Kochi, India for the use of HEMO2life® in transplant procedures. AIMS performed the world's first bilateral upper limb transplant using HEMO2life® in 2016, establishing a landmark clinical reference case.
  • Brest University Hospital (CHRU de Brest)coreStrategic or Co-development PartnerClinical trial partnership for the OxyOp2 study evaluating HEMO2life® in organ preservation applications. The hospital serves as a key clinical research site generating pivotal evidence for regulatory approvals and clinical adoption.
  • Naval Medical Research Center / US NavymajorStrategic or Co-development PartnerPreclinical collaboration with the US Navy's Naval Medical Research Center for military medical applications of HEMO2life®, including battlefield hemorrhage control, emergency field transfusion, and combat casualty care.

Scale indicators4 records

Recent moves8 records

Expansion highlights7 records

Hemarina competitors and assessment

Company assessment

Direct peers

  • NuvOx Pharma: Develops dodecafluoropentane-based oxygen therapeutics for cancer, stroke, and other ischemic conditions. Competes in the same oxygen-carrier therapeutic space with alternative chemistry approach but overlapping indications.
  • Cellphire Therapeutics: Develops Thrombosomes (lyophilized platelets) and other blood-product substitutes for hemorrhage and trauma. Operates in the same blood-substitute therapeutic space with comparable emergency medicine and military positioning.
  • Bridge to Life: Supplier of organ preservation solutions including Belzer UW and static cold storage products used as the baseline medium in transplant workflows. Competes directly with HEMO2life® as a preservation additive and could be a commercial channel partner.
  • Prolong Pharmaceuticals: Developed Sanguinate, a PEGylated bovine hemoglobin-based oxygen carrier for sickle cell disease and other ischemic conditions. Directly comparable hemoglobin-based therapeutic platform pursuing similar hematology and oxygen-delivery indications.
  • HbO2 Therapeutics: Develops Hemopure (hemoglobin-based oxygen carrier from bovine source) for surgery and trauma indications. Closest direct competitor in the HBOC therapeutic class with overlapping universal-donor positioning and surgical use cases.

Broad incumbents

  • XVIVO Perfusion: Swedish-listed organ preservation company with leading lung perfusion technology (Steen solution) and expanding into abdominal organ preservation. Established commercial player in the same transplant workflow where HEMO2life® is positioned as an additive.
  • Grifols: Global plasma-derived therapies leader producing hemoglobin-based and plasma-based blood products. Represents the established incumbent in hematology and blood-related biologics that Hemarina's marine hemoglobin platform could eventually compete with or complement.
  • OrganOx: Develops normothermic machine perfusion technology for liver and kidney preservation. Represents the leading alternative platform to HEMO2life® in the organ preservation workflow, particularly in European transplant centers.
  • TransMedics Group: Market leader in normothermic organ preservation systems for lung, heart, and liver transplants. Competes indirectly with HEMO2life® by offering an alternative preservation paradigm that may absorb or substitute for hemoglobin-based additives.

Emerging players

  • Aurum Biosciences: Develops oxygen-loaded nanobubble therapeutics for stroke and oncology. Competes in the oxygen-delivery therapeutic space with a different delivery mechanism (nanobubbles vs. extracellular hemoglobin) but overlapping clinical applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Hemarina social profiles

Digital presence

Hemarina financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hemarina leadership team

Management profile

Number of profiles

Profiles6 records

Hemarina funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hemarina M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemarina

What does Hemarina do?

Hemarina develops, manufactures, and sells medical devices and therapeutic products based on its proprietary M101 platform, leveraging extracellular hemoglobin extracted from the marine lugworm Arenicola marina. Its flagship HEMO2life® is a CE-marked organ preservation additive used in kidney, face, and limb transplants, while the broader portfolio addresses oxygen therapy, wound healing, dental care, and industrial bioproduction. The company sells these prescription products and bioprocessing inputs directly to hospitals, transplant centers, military medical institutions, and industrial customers.

Is Hemarina a public or private company?

Hemarina is a private company. It is classified as venture growth investor backed and is currently operating.

When was Hemarina founded?

Hemarina was founded in 2007. It employs 11 to 50 people.

Where is Hemarina based?

Hemarina is headquartered in Morlaix, France, in the Europe region.

How does Hemarina make money?

One revenue line is on record: HEMO2life® Medical Device Sales.

Who are Hemarina's main competitors?

Direct peers on record are NuvOx Pharma, Cellphire Therapeutics, Bridge to Life, Prolong Pharmaceuticals and HbO2 Therapeutics. Broad incumbents are XVIVO Perfusion, Grifols, OrganOx and TransMedics Group. Aurum Biosciences is listed as an emerging player.

Does Hemarina have an API?

No public API is recorded for Hemarina.

What industry is Hemarina in?

Hemarina's product category is Medical Biotechnology - Oxygen Carrier Therapeutics. Its primary akta.pro industry code is HLAIACAI, Hematology Specialty Pharmaceuticals (Non-malignant), with a secondary code of HLAAAAAL, Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
French News and Views in EnglishFrench inventor’s worm-blood burn gel helps Crans-Montana fire victimsDr. Franck Zal's worm-blood burn gel HEMHealing was used on victims of the 2026 Crans-Montana bar fire, with survivors expressing gratitude. The gel, derived from lugworm haemoglobin, was approved in Europe under a humanitarian clause and has led to Zal's nomination for the European Inventor Award. Further products, including a therapeutic oxygen carrier, are in development.openPR.comArtificial Blood Market to Reach USD 8.64 Billion by 2033 at 8.7% CAGR, Driven by Rising Demand for Blood Substitutes and Emergency Care SolutionsThe global artificial blood market reached USD 4,444.3 million in 2025 and is projected to grow to USD 8,648.0 million by 2033 at a compound annual growth rate of 8.7%, driven by increasing demand for blood substitutes and advancements in oxygen carrier technologies such as hemoglobin-based oxygen carriers and perfluorocarbon-based products. Market growth is fueled by rising trauma cases, the growing prevalence of chronic diseases, expanding surgical procedures, and the need for emergency care solutions where compatible donor blood is unavailable. Key companies including Hemarina, KaloCyte Inc., Grifols S.A., and others are expanding their artificial blood pipelines and focusing on commercialization of next-generation oxygen therapeutics, with applications spanning trauma care, military medicine, and surgical settings.GlobeNewswireArtificial Blood: Global Markets to 2028ReportLinker released a market research report on artificial blood, forecasting growth through 2028. The market is estimated to reach a value of $REDACTED million by 2028, growing at a CAGR of REDACTED%, with key players including Hemarina, VirTechBio, and NuvOx Pharma. No approved products exist for routine U.S. use, but future approvals could address unmet demand.openPR.comArtificial Blood Market Outlook 2023: Industry Share, Growth, Drivers, Emerging Technologies, and Forecast Research Report 2030 | Aurum Biosciences (U.K.), HEMARINA (France)The global artificial blood market is expected to grow significantly, driven by increasing demand for blood transfusions and limited donated blood supply. Perfluorocarbon-based oxygen carriers are expected to dominate, while hemoglobin-based carriers are gaining popularity. The market is segmented by type, application, and geography, with key players including Aurum Biosciences and HEMARINA.openPR.comArtificial Blood Substitutes Market 2020 Estimated To Expand at a Robust CAGR by 2025 | International Key Players - Hemoglobin Oxygen Therapeutics, Aurum Biosciences, HemarinaBusiness Industry Reports released a market research study on the Global Artificial Blood Substitutes Market, forecasting robust expansion through 2025 driven by demand for alternatives to human blood. The report highlights key industry players including Hemoglobin Oxygen Therapeutics, Aurum Biosciences, and Hemarina, while noting that North America is expected to lead in growth due to the presence of major ecosystem participants.Ouest-franceTop 5 des investissements. Les levées de fonds qui ont compté en 2017Five French startups raised funding in 2017: Actility led with over €70 million, followed by iAdvize's €32 million, Akeneo's €11 million, Hemarina's €8 million, and Telecom Santé's €8 million. Actility reported 338% growth over four years, while Akeneo showed 200% annual growth.